In vitro effects of some flavonoids and phenolic acids on human pyruvate kinase isoenzyme M2

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 31, Issue 2, 2016, Pages 314-317

  Aslan, Erdem ^a   Guler, Caglar ^a   Adem, Sevki ^a  

^a CANKIRI KARATEKIN UNIVERSITY   (Turkey)

Author keywords

Activation; Cancer; Flavonoid; Inhibition; Phenolic acid; PKM2

Indexed keywords

AURANTIIN; CAFFEIC ACID; CATECHIN GALLATE; EPICATECHIN; FERULIC ACID; FISETIN; FLAVONOID; GALANGIN; GALLIC ACID; GALLOCATECHIN; HESPERETIN; HESPERIDIN; KAEMPFEROL; MORIN HYDRATE; MYRICETIN; NEOERIOCITRIN; NEOHESPERIDIN; PARA COUMARIC ACID; POLYPHENOL DERIVATIVE; PROTOCATECHUIC ACID; PYRUVATE KINASE; PYRUVATE KINASE ISOENZYME M2; QUERCETIN; QUERCETIN 3 BETA DEOXY GLUCOSIDE; QUERCETIN 3 DEXTRO GALACTOSIDE; RUTOSIDE; SINAPIC ACID; SYRINGIC ACID; TAXIFOLIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; CARRIER PROTEIN; COUMARIC ACID; ENZYME INHIBITOR; HYDROXYBENZOIC ACID DERIVATIVE; MEMBRANE PROTEIN; PHENOLIC ACID; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; IC50; IN VITRO STUDY; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYME ACTIVATION; HUMAN; METABOLISM;

CARRIER PROTEINS; COUMARIC ACIDS; ENZYME ACTIVATION; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; HYDROXYBENZOATES; INHIBITORY CONCENTRATION 50; MEMBRANE PROTEINS; THYROID HORMONES;

EID: 84955493714     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2015.1022173     Document Type: Article

References (29)

1. Goel A, Mathupala SP, Pedersen PL. Glucose metabolism in cancer: evidence that demethylation events play a role in activating type II hexokinase gene expression. J Biol Chem 2003;278:15333-40.
2. Locasale JW, Cantley LC. Altered metabolism in cancer. BMC Biol 2010;8:88.
3. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013;4:e532.
4. Harris I, McCracken S, Mak TW. PKM2: A gatekeeper between growth and survival. Cell Res 2012;22:447-9.
5. Mazurek S. Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 2011;43:969-80.
6. Spoden GA, Rostek U, Lechner S, et al. Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp Cell Res 2009;315:2765-74.
7. Mazurek S, Hugo F, Zwerschke W. PKM2 (pyruvate kinase isoenzyme type M2). Atlas Genet Cytogenet Oncol Haematol 2009;13:276-81.
8. Chahar MK, Sharma N, Dobhal MP, Joshi YC. Flavonoids: A versatile source of anticancer drugs. Pharmacogn Rev 2011;5:1-12.
9. Ravishankar D, Rajora AK, Greco F, Osborn HMI. Flavonoids as prospective compounds for anti-cancer therapy. Int J Biochem Cell Biol 2013;45:2821-31.
10. Ganapathy-Kanniappan S, Geschwind JFH. Tumor glycolysis as a target for cancer therapy: Progress and prospects. Mol Cancer 2013;12:152.
11. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008;452:230-3.
12. Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis 2012; 3:e248.
13. Wu S, Le H. Dual roles of PKM2 in cancer metabolism. Acta Biochim Biophys Sinica 2013;45:27-35.
14. Orlikova B, Legrand N, Panning J, et al. Anti-inflammatory and anticancer drugs from nature. Cancer Treat Res 2014;159:123-43.
15. Khazir J, Mir BA, Pilcher L, Riley DL. Role of plants in anticancer drug discovery. Phytochem Lett 2014;7:173-81.
16. Mushtaq M, Wani SM. Polyphenols and human health-a review. Int J Pharma BioSci 2013;4:B338-60.
17. Kumar S, Narwal S, Kumar V, Prakash O. a-Glucosidase inhibitors from plants: A natural approach to treat diabetes. Pharmacogn Rev 2011;5:19-29.
18. Bansal T, Jaggi M, Khar R, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. Int J Pharm Pharm Sci 2009;12:46-78.
19. Nagao A, Seki M, Kobayashi H. Inhibition of xanthine oxidase by flavonoids. Biosci Biotechnol Biochem 1999;63:1787-90.
20. Ekinci D, Karagoz L, Ekinci D, et al. Carbonic anhydrase inhibitors: in vitro inhibition of a isoforms (hCA I, hCA II, bCA III, hCA IV) by flavonoids. J Enzyme Inhib Med Chem 2014;28:283-8.
21. Balaydin HT, Durdagi S, Ekinci D, et al. Inhibition of human carbonic anhydrase isozymes I, II and VI with a series of bisphenol, methoxy and bromophenol compounds. J Enzyme Inhib Med Chem 2012;27:467-75.
22. Koz Ö, Ekinci D, Perrone A, et al. Analysis of saponins and phenolic compounds as inhibitors of a-carbonic anhydrase isoenzymes. J Enzyme Inhib Med Chem 2014;28:412-17.
23. Ekinci D, Cavdar H, Durdagi S, et al. Structure-activity relationships for the interaction of 5, 10-dihydroindeno[1, 2-b]indole derivatives with human and bovine carbonic anhydrase isoforms I, II, III, IV and VI. Eur J Med Chem 2012;49:68-73.
24. Durdagi S, Entürk M, Ekinci D, et al. Kinetic and docking studies of phenol-based inhibitors of carbonic anhydrase isoforms I, II, IX and XII evidence a new binding mode within the enzyme active site. Bioorg Med Chem 2011;19:1381-9.
25. Sun F, Zheng XY, Ye J, et al. Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer 2012;64:599-606.
26. Adhami VM, Syed DN, Khan N, Mukhtar H. Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol 2012;84:1277-81.
27. Damia G, Garattini S. The pharmacological point of view of resistance to therapy in tumors. Cancer Treat Rev 2014;40: 909-16.
28. Sullivan EJ, Kurtoglu M, Brenneman R, et al. Targeting cisplatinresistant human tumor cells with metabolic inhibitors. Cancer Chemother Pharmacol 2014;73:417-27.
29. Lisanti MP, Martinez-Outschoorn UE, Sotgia F. Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and ''fibroblast addiction'' are new therapeutic targets for drug discovery. Cell Cycle 2013;12:2723-32.